Interim FDG-PET Imaging in Lymphoma

被引:24
作者
Gallamini, Andrea [1 ]
Zwarthoed, Colette [2 ]
机构
[1] A Lacassagne Canc Ctr, Res Innovat & Stat Dept, Nice, France
[2] A Lacassagne Canc Ctr, Nucl Med Dept, Nice, France
关键词
POSITRON-EMISSION-TOMOGRAPHY; B-CELL LYMPHOMA; STAGE HODGKINS LYMPHOMA; PROGRESSION-FREE SURVIVAL; PERIPHERAL T-CELL; EARLY F-18-FDG PET; RESPONSE ASSESSMENT; PROGNOSTIC VALUE; OPEN-LABEL; INTERPRETATION CRITERIA;
D O I
10.1053/j.semnuclmed.2017.09.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary mediastinal B-cell lymphoma. A large body of evidence exists in most lymphoma subtypes stressing the role of iPET for early chemotherapy response during first-line chemotherapy treatment, but an increased number of reports have recently been published focusing on the role of iPET in relapsed or refractory lymphoma to predict treatment outcome. Varying patterns of FDG uptake was observed across various lymphoma entities; hence, interpretation of FDG-PET scans should be in the context of the tumor architecture and the prevalence of cellular population, in particular, neoplastic vs non-neoplastic inflammatory cells present in tissue microenvironment. In the second part of the article, the authors reviewed the iPET response adapted clinical trials and the clinical benefits of this strategy compared to standard non PET adapted therapy. In particular, the authors extrapolated the reproducibility of FDG-PET image interpretation and the feasibility of a timely treatment adaptation based on FDG-PET results in daily clinical practice. This is essential for the reader, as the iPET-adapted strategy has become the standard of care in both early- and advanced-stage Hodgkin lymphoma, and, in the future, probably this strategy will be expanded to primary mediastinal B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 50 条
  • [41] Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis
    Adams, Hugo J. A.
    Kwee, Thomas C.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 337 - 347
  • [42] Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma
    Wight, Joel
    Wai, Shin Hnin
    Shen, Edward
    Lee, Sze-Ting
    Berlangieri, Salvatore
    Fancourt, Tineke
    Hawkes, Eliza
    Hannah, Anthony
    Leung, Teresa
    Chong, Geoffrey
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (04) : 475 - 483
  • [43] FDG-PET in the clinical management of Hodgkin lymphoma
    Hutchings, M
    Eigtved, AI
    Specht, L
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 52 (01) : 19 - 32
  • [44] Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial
    Schoder, Heiko
    Polley, Mei-Yin C.
    Knopp, Michael, V
    Hall, Nathan
    Kostakoglu, Lale
    Zhang, Jun
    Higley, Howard R.
    Kelloff, Gary
    Liu, Heshan
    Zelenetz, Andrew D.
    Cheson, Bruce D.
    Wagner-Johnston, Nina
    Kahl, Brad S.
    Friedberg, Jonathan W.
    Hsi, Eric D.
    Leonard, John P.
    Schwartz, Lawrence H.
    Wilson, Wyndham H.
    Bartlett, Nancy L.
    BLOOD, 2020, 135 (25) : 2224 - 2234
  • [45] FDG-PET in Lymphoma: Nuclear Medicine Perspective
    Cerci, Juliano Julio
    Zanoni, Lucia
    Meneghetti, Jose C.
    Fanti, Stefano
    PET CLINICS, 2012, 7 (01) : 21 - +
  • [46] Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma
    Kluge, R.
    Koerholz, D.
    KLINISCHE PADIATRIE, 2011, 223 (06): : 315 - 319
  • [47] Current Role of FDG-PET in Pediatric Hodgkin's Lymphoma
    Kluge, Regine
    Kurch, L.
    Georgi, Thomas
    Metzger, Monika
    SEMINARS IN NUCLEAR MEDICINE, 2017, 47 (03) : 242 - 257
  • [48] Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma: Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET
    Halasz, Lia M.
    Jacene, Heather A.
    Catalano, Paul J.
    Van den Abbeele, Annick D.
    LaCasce, Ann
    Mauch, Peter M.
    Ng, Andrea K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (05): : E647 - E654
  • [49] The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma
    Avigdor, Abraham
    Sirotkin, Tsvi
    Kedmi, Meirav
    Ribakovsy, Elena
    Berkowicz, Miriam
    Davidovitz, Yaron
    Kneller, Abraham
    Merkel, Drorit
    Volchek, Yulia
    Davidson, Tima
    Goshen, Elinor
    Apter, Sara
    Shimoni, Avichai
    Ben-Bassat, Isaac
    Nagler, Arnon
    ANNALS OF HEMATOLOGY, 2014, 93 (08) : 1297 - 1304
  • [50] Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma
    Boo, Sun Ha
    Hyun, Joo O.
    Kwon, Soo Jin
    Yoo, Ie Ryung
    Kim, Sung Hoon
    Park, Gyeong Sin
    Choi, Byung Ock
    Jung, Seung Eun
    Cho, Seok-Goo
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 53 (04) : 263 - 269